Research Article
A Decade of Experience Using mTor Inhibitors in Liver Transplantation
Table 1
Recipient demographics.
| | Variable | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
| | 328 | 135 | 15 | 156 | 38 | | Age (median years) | 52 | 52 | 50 | 50 | 50 | | MELD (median) | 22 | 22 | 24 | 18** | 18 | | Gender male (%) | 68.3 | 63 | 80 | 61.5 | 81.6 | | Donor age (median years) | 32 | 30 | 35 | 30.5 | 33 | | CIT (median minutes) | 352.5 | 373 | 342 | 334 | 279 | | WIT (median minutes) | 33.5 | 32 | 36 | 36 | 38.5 | | Live donor (%) | 15.2 | 8.1* | 13.3 | 20.5 | 28.9 | | Ethnicity (%) | | | | | | | Caucasian | 74.4 | 74.07 | 73.3 | 76.3 | 73.3 | | African American | 1.8 | 0.00 | 0.00 | 1.9 | 0.00 | | Hispanic | 19.21 | 18.52 | 20.00 | 17.31 | 23.68 | | Asian | 4.57 | 6.67 | 6.67 | 4.49 | 0.00 | | American Indian | 0.00 | 0.74 | 0.00 | 0.00 | 2.63 | | BMI (median) | 25.4 | 25.7 | 28.1 | 25.9 | 26.3 | | Pre-GFR (median) | 80.4 | 66.8 | 60.3 | 82.7 | 88.7 | | Primary transplant indication (%) | | | | | | | HCC | 30.8 | 26.7 | 33.3 | 19.9 | 23.7 | | HCV | 53.7 | 39.3 | 53.3 | 38.5* | 50.0 | | PSC | 11.3 | 14.1 | 0.0 | 14.1 | 13.2 | | ETOH | 7.0 | 10.4 | 26.7 | 12.2 | 7.9 | | HBV | 6.1 | 5.9 | 13.3 | 8.3 | 5.3 | | AIH | 4.3 | 8.1 | 0.0 | 7.1 | 10.5 | | NASH | 1.5 | 2.2 | 6.7 | 3.2 | 0.0 | | PBC | 3.7 | 1.5 | 0.0 | 7.1 | 2.6 | | Cryptogenic cirrhosis | 7.6 | 8.1 | 0.0 | 6.4 | 5.3 | | Budd-Chari | 1.2 | 2.2 | 0.0 | 0.6 | 5.3 |
|
|
Statistically significant values are bolded: *, **.
|
